# US 2012/0251498 A1 · Gene Delivery to Organs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251498 A1
- Document ID: US20120251498A1
- Status: Published application
- Kind: A1
- Application number: 13/465,255
- Filed: 2012-05-07
- Published: 2012-10-04
- Earliest claimed: 2003-06-04
- Assignees: The Johns Hopkins University
- Inventors: J. Kevin Donahue; Amy D. McDonald; Kan Kikuchi
- Web page: https://patentgrep.com/patent/US20120251498A1

## CPC

- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 13/10: of the bladder
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Application of a virus with poloxamer alone onto atria results in diffuse epicardial gene transfer with negligible penetration into the myocardium. Progressive increases in protease concentration, however, allow transmural gene transfer. After protease exposure, echocardiographic left atrial diameter does not change. Left atrial ejection fraction decreases on post-operative day 3, but returns to baseline by day 7. At appropriate protease concentrations, tissue tensile strength is unaffected by the procedure. Transmural atrial gene transfer can be effected using this direct “painting” method.

## Claims

### Claim 1

A method of delivering a nucleic acid to an organ, comprising:
applying a composition to the external surface of the organ, wherein the composition comprises:
an adenovirus comprising the nucleic acid;
a poloxamer; and
trypsin.

### Claim 2 (depends on 1)

The method of claim 1 wherein the poloxamer is F127.

### Claim 3 (depends on 1)

The method of claim 1 wherein the poloxamer is L61.

### Claim 4 (depends on 1)

The method of claim 1 wherein the poloxamer is present at a concentration of 5-30% in the composition.

### Claim 5 (depends on 1)

The method of claim 1 wherein the poloxamer is present at a concentration of 15-25% in the composition.

### Claim 6 (depends on 1)

The method of claim 1 wherein the poloxamer is present at a concentration of 20% in the composition.

### Claim 7 (depends on 1)

The method of claim 1 wherein the trypsin is present at a concentration of 0.05% to 0.5% in the composition.

### Claim 8 (depends on 1)

The method of claim 1 wherein the organ is a heart.

### Claim 9 (depends on 1)

The method of claim 1 wherein the surface of the organ is an atrial epicardial surface.

### Claim 10 (depends on 1)

The method of claim 1 wherein the nucleic acid encodes a protein and the protein is expressed in cells of the organ.

### Claim 11 (depends on 1)

The method of claim 1 wherein the organ is a hollow organ.

### Claim 12 (depends on 1)

The method of claim 1 wherein the organ is a gastrointestinal organ.

### Claim 13 (depends on 1)

The method of claim 1 wherein the organ is a reproductive organ.

### Claim 14 (depends on 1)

The method of claim 1 wherein the organ is selected from the group consisting of: stomach, gall bladder, small intestine, large intestine, rectum, uterus, and urinary bladder.

### Claim 15 (depends on 1)

The method of claim 1 wherein the organ is selected from the group consisting of: eye, skin, diaphragm, and lung.

### Claim 16 (depends on 1)

The method of claim 1 wherein the organ is in an animal's body.

### Claim 17 (depends on 1)

The method of claim 1 wherein the organ is outside of an animal's body.

### Claim 18 (depends on 1)

The method of claim 1 wherein the organ is a blood vessel.

### Claim 19 (depends on 9)

The method of claim 9 wherein the nucleic acid comprises a dominant negative mutation for rapid component of delayed rectifier potassium current wherein the dominant negative mutation comprises a mutation in a HERG gene.

### Claim 20 (depends on 9)

The method of claim 9 wherein the nucleic acid comprises a HERG-G628S allele.

### Claim 21 (depends on 19)

The method of claim 19 wherein the nucleic acid comprises a dominant negative mutation for the rapid component of the delayed rectifier potassium current.

### Claim 22 (depends on 19)

The method of claim 19 wherein the nucleic acid comprises a HERG-G628S allele.
